Trudhesa® (dihydroergotamine mesylate) nasal spray | Official Healthcare Professional (HCP) Site | Impel NeuroPharma®
Ready to deliver relief3,4
Today, with Precision Olfactory Delivery (POD®) technology, patients can have the proven efficacy of dihydroergotamine mesylate (DHE) on demand for rapid, sustained, consistent relief, even when taken late into a migraine attack.2,4-7
Exploratory endpoints and post hoc analyses of patient-reported efficacy data for some patients showed the following results7*:
Rapid
Pain relief in as fast as 15 minutes6
Sustained
Pain freedom lasted 2 days with 1 dose8
Consistent
Delivered results time after time6
No dosing window
Relief on their terms, even when taken late into a migraine attack5-7
*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa®.7
Watch what experts are saying about Trudhesa
Learn about how Trudhesa delivers migraine relief, sending medication to the upper nasal space, and how DHE has changed over the years.
The evolution of DHE for at-home use
Sheena Aurora, MD
Determining the most appropriate acute treatment
Peter McAllister, MD, FAAN
POD®: Beyond just another nasal spray
Peter McAllister, MD, FAAN
Treating migraine effectively through the nose
Wade Cooper, DO
Trudhesa Difference
References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Aurora S, Hocevar-Trnka J, Shrewsbury S. Acute treatment of migraine with INP104: exploratory efficacy from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Pharmaceuticals. 2020. 7. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients [published online ahead of print, 2021 Aug 7]. Headache. 2021;10.1111/head.14184. doi:10.1111/head.14184. 8. Tepper SJ, Ailani J, Shrewsbury SB, Aurora SK. Recurrence rates for INP104 for the acute treatment of migraine: results from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021.